NEW YORK ( TheStreet) -- Genoptix ( GXDX) soared in Monday's extended session following a Bloomberg report that the company is putting itself on the auction block. Citing two people with "knowledge of the process," the article states Genoptix has hired Barclays plc to handle the sale. The Carlsbad, Calif.-based company wasn't immediately available for comment. The stock was last quoted at $21.05, up 17%, on volume of nearly 30,000, according to Nasdaq.com. Based on a regular session close at $17.98, the shares were down about 49% so far in 2010. The stock has seen a slight bounce since scraping its 52-week low of $15.50 on June 24 but it's still off 54% since hitting its high for the year of $39 on May 5. The company's market capitalization was around $316 million. Genoptix provides diagnostic test services related to hematology and oncology. The company reported its fiscal third-quarter results on Nov. 4, posting a profit of $4.4 million, or 24 cents a share, for the three months ended Sept. 30 on revenue of $49.5 million. The EPS performance was 11% ahead of Wall Street's consensus estimate for earnings of 22 cents a share in the September period.
>To submit a news tip, send an email to: firstname.lastname@example.org